Imatinib Kern Pharma (Imatinib)

Imatinib acts on malignant cells driven by specific tyrosine‑kinase pathways and is used in several hematologic and solid‑tumor indications.

• Chronic myeloid leukemia (CML): provides disease control by inhibiting the BCR‑ABL fusion protein.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): helps achieve remission through the same BCR‑ABL blockade.
• Gastrointestinal stromal tumor (GIST): reduces tumor growth by blocking c‑KIT and PDGFR signaling.

• Imatinib selectively inhibits the ATP‑binding site of BCR‑ABL tyrosine kinase, preventing phosphorylation of downstream substrates that drive uncontrolled cell proliferation. It also blocks the activity of c‑KIT and platelet‑derived growth factor receptors (PDGFR), thereby interfering with signaling pathways essential for the survival of certain malignant cells.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Nausea and vomiting: gastrointestinal upset occurring in many patients.
• Edema: peripheral swelling, often of the hands or feet.
• Muscle cramps: intermittent painful contractions.
• Fatigue: generalized tiredness.
• Diarrhea: loose stools, sometimes persistent.

Serious or Rare Side Effects

• Hepatotoxicity: elevated liver enzymes or liver injury.
• Cardiotoxicity: reduced left‑ventricular ejection fraction.
• Severe neutropenia: marked drop in white blood cells increasing infection risk.
• Hemorrhagic events: unusual bleeding or bruising.

Patients and prescribers should consider several safety measures before and during therapy.

• Cardiac monitoring: assess baseline and periodic ejection fraction in patients with cardiac risk.
• Hepatic function: check liver enzymes before initiation and during treatment.
• Pregnancy risk: avoid use in pregnancy; discuss contraception and potential fetal harm.
• Drug interactions: review concomitant medications that affect CYP3A4 metabolism.
• Renal impairment: adjust monitoring in patients with reduced kidney function.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Imatinib may interact with other medicines that influence its metabolism or pharmacodynamic profile.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may markedly reduce imatinib exposure.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can increase plasma levels and toxicity risk.

Moderate Interactions (Monitor Closely)

• Antacids containing aluminum or magnesium: may affect absorption; separate dosing by at least 2 hours.
• Proton‑pump inhibitors: may modestly reduce bioavailability.
• Warfarin: monitor INR as imatinib can potentiate anticoagulant effect.
• Vaccines: live vaccines should be avoided during treatment.
• Diuretics: monitor electrolytes, especially potassium, as imatinib can cause hypokalemia.